FDA Adverse Event Malfunction Summary report: N

CREATININE PLUS VER.2

MDR report key: 2173032 · Received July 23, 2011

Report

Report Number
1823260-2011-03908
Event Type
Malfunction
Date Received
July 23, 2011
Date of Event
June 30, 2011
Report Date
August 31, 2011
Manufacturer
ROCHE DIAGNOSTICS
Product Code
JFY
PMA / PMN Number
K024098
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
PA, US
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

OTHER ASSAYS RELATED TO THIS EVENT ARE REPORTED IN MEDWATCH REPORTS WITH PATIENT IDENTIFIERS: (B)(6).

Additional Manufacturer Narrative · 1

FURTHER INVESTIGATION COULD NOT BE PERFORMED AS ADDITIONAL INFORMATION WAS NOT PROVIDED. THE CUSTOMER CHANGED THE SAMPLE PROBE WHICH APPEARED TO RESOLVE THE ISSUE. THE ISSUE HAS NOT RECURRED. NO ADVERSE EVENTS WERE REPORTED.

Description of Event or Problem · 1

THE USER RECEIVED QUESTIONABLE CREATININE RESULTS FROM THE COBAS C501 SERIAL NUMBER (B)(4). OF THE DATA PROVIDED, THE RESULTS FOR ONE PATIENT SAMPLE WERE DISCREPANT. ALL RESULTS ARE IN MG/DL. THE INITIAL RESULT WAS 1.0. THE REPEAT RESULT ON ANOTHER COBAS C501 ANALYZER WAS 1.3 WITH A DATA FLAG AND ON ANOTHER COBAS C501 ANALYZER WAS 1.3 WITH A DATA FLAG TWICE. THE INITIAL RESULT WAS REPORTED OUTSIDE THE LABORATORY. THE USER REFUSED TO PROVIDE INFORMATION CONCERNING IF THE PATIENTS WERE ADVERSELY AFFECTED AS SHE STATED SHE HAD NO WAY TO DETERMINE THIS. NO CORRECTIVE REPORTS WERE GENERATED. UPON EVALUATION OF THE ANALYZER, THE FIELD SERVICE REPRESENTATIVE DETERMINED THERE WAS A FLUIDIC FAILURE OF THE SAMPLE PROBE. THE USER REPLACED THE SAMPLE PROBE. TO VERIFY THE ANALYZER OPERATION, THE FIELD SERVICE REPRESENTATIVE RAN CALIBRATION, QUALITY CONTROL AND PERFORMANCE TESTING WITH ALL RESULTS WITHIN SPECIFICATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 CREATININE PLUS VER.2 ENZYMATIC METHOD, CREATININE JFY ROCHE DIAGNOSTICS NA 64024401

Patients

Seq Age Sex Outcome Treatment
1 088 YR